Analytical and clinical evaluation of a new tumor marker in breast cancer: CA 27.29.
Evaluation of a radioimmunoassay for a new tumor marker, named CA 27.29, recently proposed for use in breast cancer patients, is reported in this study. After considering the analytical performance, the clinical study was directed to a control group of 66 apparently healthy subjects (Controls), a group of 25 women with benign breast disease (BBD) and a group of 164 breast cancer patients divided into primary before any treatment (M-), in follow-up with no evidence of disease (NED) and presence of metastases (M+). When compared to CA 15.3, our results showed similar sensitivity of both markers with a slightly lower specificity for CA 27.29. In some cases, however, CA 27.29 elevation appears earlier than CA 15.3 as a sign of metastases. We thus propose their associated use.
Correale
M
M
Clinical Chemistry Lab.-RIA Unit, Bari, Italy.
Abbate
I
I
Gargano
G
G
Catino
A
A
Dragone
C D
CD
Musci
M D
MD
Serio
G
G
Paradiso
A
A
De Lena
M
M
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood* / Q000276:immunology; D001943:Breast Neoplasms / Q000097:blood / Q000175:diagnosis / Q000276:immunology*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D011863:Radioimmunoassay / Q000379:methods / Q000706:statistics & numerical data; D012680:Sensitivity and Specificity
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor